MENA 2024 Recordings-Metabolic Dysfunction– Associated Liver Disease (MASLD)

Metabolic Dysfunction– Associated Liver Disease (MASLD) - Dr. Betul Hatipoglu

Video Transcription

Video Summary

The talk focuses on the evolving understanding and medical management of fatty liver disease, specifically transitioning from the term NAFLD (Non-Alcoholic Fatty Liver Disease) to MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease). The speaker highlights the global prevalence of the condition and emphasizes that it not only affects liver health but also increases the risk of cardiovascular diseases, non-liver cancers, and complications leading to liver transplantation. MASLD is characterized by excess liver fat accompanied by at least one cardiometabolic risk factor, distinguishing it from conditions caused by alcohol or medication. Diagnosis involves screening tools like the FIB-4 score to assess fibrosis risk and potential liver damage. The talk also covers management strategies, including lifestyle changes, weight loss, and medication, noting the significance of new drugs like Resmetirone for reversing liver fibrosis. The speaker stresses the importance of individualized treatment approaches, taking into account patient-specific factors such as age, existing health conditions, and risk profiles. Overall, the session offers insights into the intricate dynamics of liver disease management, from diagnosis to therapeutic interventions.

Keywords

MASLD

fatty liver disease

cardiovascular risk

FIB-4 score

liver transplantation

Resmetirone

individualized treatment